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Background/aims: To evaluate the potential protective effects of Ankaferd blood stopper (ABS) in an experimental obstructive jaundice
(OJ) model.
Materials and methods: The study included 26 female rats, which were divided into 3 groups. The sham group, consisting of 10 rats,
(group 1) only received solely laparotomy. In the control group, consisting of 8 rats, (group 2), ligation was applied to the biliary tract
and no treatment was implemented. In the treatment group, consisting of 8 rats, (group 3), following ligation of biliary tract, 0.5 mL/day
ABS was given for 10 days. Liver tissue and blood samples were taken for histopathological and biochemical examination.
Results : Compared to group 2, group 3 had higher aspartate aminotransferase (AST), total oxidant status (TOS) malondialdehyde
(MDA), fluorescent oxidant products (FOP), and lower expression of albumin and total antioxidant status (TAS) (P < 0.05). In
histopathological analysis, the mean scores of all histopathological parameters (fibrosis, portal inflammation, confluent necrosis,
interphase activity, bile duct proliferation) have statistical significance between group 2 and group 3 (P < 005).
Conclusions: ABS has promising results in the treatment of experimental OJ because of its antioxidant and antiinflammatory properties.
It may be used in clinical practice after more extensive studies about the effects of ABS on OJ.
Key words: Obstructive jaundice, Ankaferd blood stopper, antioxidant

1. Introduction
Obstructive jaundice (OJ) occurs with blockage of the bile
stream in the extrahepatic or intrahepatic biliary tract.
This obstruction in the pathway of bile synthesis through
the gastrointestinal system causes cholestasis [1].
The hepatotoxic effects of bile acids, oxidative stress and
lipid peroxidation are the main issues for liver damage
caused by cholestasis [2]. Complications of insufficient
treatment are cholangitis, coagulation disorders, biliary
fibrosis and hepatic damage leading to cirrhosis [3].
Therefore, various agents and methods have been studied
to decrease the damage caused by obstructive jaundice,
but these agents are not medications that are widely used
in clinical practice [4].
Ankaferd blood stopper (ABS) (Ankaferd Health
Products Ltd., İstanbul, Turkey) is a topical haemostatic
agent of plant origin that has come into use in recent years.

ABS forms an encapsulated protein network that provides
critical junction points for rapid erythrocyte aggregation
without affecting physiological coagulation systems [5].
In addition to haemostatic functions, antiinflammatory,
antiinfective, antifungal, and antioxidative effects have
been attributed to ABS [6–8]. This herbal medication
contains a standard combination of Thymus vulgaris,
Glychrriza glabra, Vitris vinifera, Alpina officinarum,
and Urtica dioicayi. Each of these plants has effects on
endothelial and blood cells, angiogenesis, cell proliferation,
vascular dynamics and interaction between cells. There are
some examples of T. vulgaris having an antioxidant effect
by inhibiting lipid peroxidation and U. Dionica has been
shown to cause vasodilatation by inducing nitric oxide
(NO) synthesis from the vascular endothelium. There are
limited studies on clinical and experimental usage of ABS
in hepatic surgeries [5].
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The aim of this experimental study was to investigate
the effects of ABS on experimental obstructive jaundice
through the evaluation of oxidative stress and pathological
changes. To the best of our knowledge, this is the first
study in the literature to have examined the effect of ABS
on hepatic damage caused by obstructive jaundice.
2. Material and methods
The approval for this study was granted by the Animal
Research Ethics Committee of Ankara Training and
Research Hospital and all procedures were applied in
accordance with the principles of the National Guidelines
for Experimental Use of Laboratory Animals.
2.1. Animals
The study sample consisted of 30 female adult Wistar albino
rats, each with a weight of 230 ± 22 g. The rats were housed
in cages made of wire netting at a permanent temperature
of 21 ± 2 °C with a 12-h light/dark cycle. The animals had
a diet consisting of standard laboratory supply chow and
water ad libitum. Access to food and access to water for
the rats was stopped 12 h and 2 h prior to anaesthesia,
respectively.
2.2. Surgery and experimental protocol
This research aimed to investigate the effects of Ankaferd
blood stopper on obstructive jaundice. The group plans
are explained below:
Group 1: Laparotomy was applied, and then the
choledochus was dissected from adjacent tissues. No other
treatment was given.
Group 2: Laparotomy was applied, and then the
choledochus was dissected from adjacent tissue and tied
twice with 5/0 silk sutures. The choledochus was cut
between the sutures. No other intervention or medication
was given.
Group 3: Laparotomy was applied and then the
choledochus was dissected from adjacent tissues and
tied twice with 5/0 silk sutures. The choledochus was
cut between the sutures. Ankaferd blood stopper was
administered by orogastric catheter at a dose of 0.5 mL per
day.
After the procedures, each abdominal incision was
closed with 3/0 silk sutures. Subsequently, the rats were
allowed to feed. After 10 days, the rats were slaughtered
with high dose ketamine, and then laparotomy was
performed. In laparotomy, blood samples were taken from
the aorta for histopathological and biochemical analyses,
and a 40 mg tissue sample was taken from the liver as
excision.
2.3. Biochemical analysis
The evaluation of the liver functions in the serum was
carried out in the Biochemistry Department of Ankara
Training and Research Hospital. Albumin (ALB), aspartate
aminotransferase (AST), alanine aminotransferase (ALT),

total bilirubin (T. BIL), and direct bilirubin (D. BIL) were
measured using a Roche Cobas 8000 chemistry analyser
(Roche Diagnostics, Risch-Rotkreuz, Switzerland).
The parameters of oxidative stress were evaluated in
the Biochemistry Department of Ankara Training and
Research Hospital. Liver tissues were kept at −80 °C until
the day of the analysis. Total antioxidant status (TAS),
total oxidant status (TOS), malondialdehyde (MDA)
and fluorescent oxidation products (FOP) levels were
determined.
TAS and TOS levels were measured by applying the
TAS and TOS kits of Rel Assay Diagnostic to the Roche
Cobas 6000 instrument (company, city, country?)
In the TAS measurement, antioxidants in the
sample reduce dark blue-green coloured 2,2′-azino-bis
(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical to
colourless reduced ABTS form. The change of absorbance
at 660 nm is related with the total antioxidant level of the
sample. The assay is calibrated with a stable antioxidant
standard solution, which is traditionally named as Trolox
Equivalent, which is a vitamin E analogue.
In the TOS measurement, oxidants present in the
sample oxidise the ferrous ion chelator complex to ferric
ion. The oxidation reaction is prolonged by enhancer
molecules, which are abundantly present in the reaction
medium. The ferric ion makes a coloured complex with
chromogen in an acidic medium. The colour intensity,
which can be measured spectrophotometrically, is related
to the total amount of oxidant molecules present in the
sample. The assay is calibrated with hydrogen peroxide.
TAS and TOS results are given in µmol/g protein.
MDA acts as a lipid peroxidation indicator and is
a known tissue injury index. The levels of MDA were
measured using the fluorometric method, in line with the
description of Wasowicz et al. [9]. Following the reaction
between thiobarbituric acid (TBA) and MDA, the reaction
product was isolated in butanol, then a spectrofluorometric
measurement was taken at a wavelength of 547 nm for
emission and 525 nm for excitation. The standard was
designated as a 0–5 µmol/L 1,1’,3,3’ tetraethoxypropane
solution. Then, 50 µL homogenate was introduced into 10
ml glass tubes, each with 1 ml of distilled water in order
to measure MDA levels in tissue. Following this step, 1
mL solution containing 29 mmol/L TBA was added to
acetic acid and mixed. The samples were exposed to heat
of between 95 °C and 100 °C for a period of 1 h using a
water bath. After cooling the heated samples, they were
mixed with 25 µL of 5 mol/L hydrochloric acid (HCL) and
agitation was applied for a period of 5 min to extract the
mixture of the reaction using 3.5 mL n-butanol. Following
the separation of the butanol phase through centrifugation
for 10 min at 1500 g, a fluorometer (HITACHI F-2500,
Japan) was used to measure the fluorescence in the butanol
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extract at 547 nm and 525 nm wavelengths for emission
and excitation, respectively. Solutions of 0–5 µmol/L
1,1’,3,3’ tetraethoxypropane were utilised as standard. The
levels of MDA were shown as nmol/g protein.
Homogenised tissues were isolated using ethanol-ether
(3/1, v/v) for FOP measurements, then these tissues were
evaluated through a spectrofluorometer at wavelengths of
360 nm and 430 nm (wavelengths for excitation/emission)
[10].
2.4. Histopathological evaluation
The liver tissue samples of each rat were preserved in storage
containers including 10% formol. The tissue samples were
sliced into strips at 3mm intervals and paraffin waxed
into tissue cassettes for macroscopic investigation. The
paraffin wax blocks were sliced into 4-micron sections and
stained with H/E and Masson trichrome. The pathological
evaluation was made by a single pathologist blinded to
the groups. The samples were examined under a light
microscope at × 40, × 100, × 200 and × 400 magnification.
Histopathological changes were evaluated using the
modified histological activity index scoring system (HAI).
The HAI scoring system includes a total of five parameters
as focal necrosis, portal inflammation, interphase hepatitis,
confluent necrosis and fibrosis. Focal necrosis was graded
as: none 0; Single focus at ×10 magnification - 1 (mild);
2–4 focus - 2 (moderate); 5–10 focus - 3 (severe), and
>10 focus - 4 (extremely severe). Portal inflammation was
graded as: none 0; mild and in some or all portal areas 1 (mild); moderate and in some or all portal areas - 2
(moderate); moderately significant and in all portal
areas - 3 (severe), and significant and in all portal areas
- 4 (extremely severe). Interphase hepatitis was graded
as: none 0; mild and focal or in some portal areas - 1
(mild); mild/moderate and focal or in most portal areas
- 2 (moderate); moderate and in %50 > of portal areas or
septum - 3 (severe), and severe and > %50 of portal areas
or septum - 4 (extremely severe). Confluent necrosis was
graded as: none (0/0); focal confluent necrosis - mild
(1/1); zone 3 necrosis in some areas - moderate (2/2);
zone 3 necrosis in most areas - moderate (2/3); zone 3
necrosis and also a few portal-central bridging necrosis severe (3/4); zone 3 necrosis and also numerous portalcentral bridging necrosis - severe (3/5), and panacinar or
multiacinar necrosis - extremely severe (4/6). Fibrosis was
graded as: none (0/0); fibrosis extension in some portal
areas - mild (1/1); fibrosis extension in most of portal areas
- mild (1/2); fibrosis extension in most of portal areas and
also rare portoportal bridging - moderate (2/3); fibrosis
extension in most of portal areas and also significant
portoportal or portocentral bridging - moderate (2/4);
significant portoportal or portocentral bridging and
also rare nodules - severe (3/5), and probable or definite
cirrhosis - extremely severe (4/6).
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Another parameter investigated beyond the HAI
scoring was bile duct proliferation. In grading of bile duct
proliferation, consecutive 5 areas in × 100 magnification
were counted, and each proliferation was categorised as 0
(none), 1 (mild), 2 (moderate), and 3 (severe). Then, these
numbers were averaged and categorised again similarly.
Masson trichrome dye was used for the evaluation of
fibrosis.
2.5. Statistical analysis
The data were analysed statistically using SPSS 22.0 software
(IBM Corporation, Armonk, NY, USA). The Shapiro–
Wilk’s test, skewness, and kurtosis values were used to
analyse the data distribution. The data were presented
as mean +/- SD or median (min-max) where applicable.
The statistical analysis of the results was performed using
unpaired Student’s t-tests and ANOVA models (with
Tamhane’s post hoc test) with normally distributed data.
For other types of data, the Mann–Whitney U test and the
Kruskal–Wallis tests were used. The association between
categorical variables was tested using the chi-square test or
Fisher’s exact test. Significance was considered as P < 0.05.
3. Results
3.1. General
Throughout the study period, 2 rats from group 2 and 2
rats from group 3 died.
3.2. Oxidative stress parameters
Oxidative stress parameters are shown in Table 1 (TAS,
TOS, MDA, and FOP). When TAS levels were compared
between group 3 and group 2, the TAS levels in group 3
were found to be significantly higher than group 2 (P <
0.05). When group 3 and group 1 were compared, the
TAS level was found to be significantly lower in group 3
(P < 0.05). When the TOS, MDA, and FOP levels were
compared between group 3 and group 2, a statistically
significant decrease was found (P < 0.05). When these
parameters were compared between group 3 and group 1,
they were found to be significantly higher (P < 0.05).
3.3. Liver function tests
The mean values of the liver function tests (ALB, AST,
ALT, T.BIL, D.BIL) are summarised in Table 2. When
group 2 and group 3 were compared, ALT levels were
lower in group 3 but not to a statistically significant level
(P = 0.691). Significant differences were determined
irrespective of the ALB and AST values.
3.4. Histopathological analysis
Histopathological analyses according to the HAI scoring
are given in Table 3. According to the statistical analysis
of the HAI scores, statistically significant changes were
found in all parameters between group 1 and group 2 (P <
0.05) (as shown in Figure 1, 2, and 3). Fibrosis, interphase
activity and bile duct proliferation scores were statistically
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Table 1. Oxidative stress parameters of the groups.

Group 1 (Sham)

TAS
(mean ± SD)
(µmol/g protein)
204.43 ± 13.27a b

TOS
(mean ± SD)
(µmol/g protein)
17.6 ± 3.99a d

MDA
(mean ± SD)
(nmol/g protein)
9.17 ± 3.12a d

FOP
(mean ± SD)
(FP/g protein)
6.23 ±1.4a d

Group 2 (control)

157.85 ± 13.90a c

33.19 ± 4.04a e

24.61 ± 5.38a f

21.81 ±5.6a g

Group 3 (ABS)
180.74 ± 13.93b c
a) P < 0.001 for Group 1 versus Group 2
b) P = 0.007 for Group 1 versus Group 3
c) P = 0.016 for Group 2 and Group 3
d) P < 0.001 for Group 1 and Group 3
e) P = 0.022 for Group 2 versus Group 3
f) P = 0.044 for Group 2 versus Group 3
g) P = 0.047 for Group 2 versus Group 3

27.24 ± 3.54d e

18.43 ± 2.56d f

15.54 ±2.11d g

Groups

Total antioxidant status (TAS), total oxidant status (TOS), malondialdehyde (MDA), fluorescent oxidant products (FOP), Ankaferd
blood stopper (ABS)
*P values were calculated using the Kruskal–Wallis test.
Table 2. Liver function parameters of the groups.
Albumin
(g/dl)
(mean ± SD)
3.80 ± 0.15a b

T Bilirubin
(mg/dl)
(mean ± SD)
0.06 ± 0.01a b

D Bilirubin
(mg/dl)
(mean ± SD)
0.03 ± 0.01a b

825.25 ± 247.69a c

1.99 ± 0.16a d

7.46 ± 1.04a

7.46 ± 1.04a

547.00 ± 107.44b

2.83 ± 0.39b

7.62 ± 1.4

7.62 ± 1.44b

Groups

ALT (U/L)
(mean ± SD)

AST (U/L)
(mean ± SD)

Group 1 (Sham)

66.50 ± 11.36a b

177.60 ± 29.44a b

Group 2 (control)

412.13 ± 118.83a

Group 3 (ABS)
355.75 ± 100.63
a) P < 0.001 for Group 1 versus Group 2
b) P < 0.001 for Group 1 versus Group 3
c) P = 0.048 for Group 2 and Group 3
d) P = 0.001 for Group 2 versus Group 3
b

c

d

b

Aminotransferase (AST), alanine aminotransferase (ALT), standard deviation (SD), total (T), direct (D), Ankaferd blood stopper (ABS)
*P values were calculated using the Kruskal–Wallis test.
Table 3. The histopathological scores of the groups.

Groups

Fibrosis
Portal
Interface activity
Focal inflammation Confluent necrosis
Bile duct proliferation
median
inflammation
median (minmedian (min-max) median (min-max)
median (min-max)
(min-max) median (min-max)
max)

Group 1 (Sham)

0 (0–1)a b

Group 2 (control) 3 (1–3)a c

0 (0–1)d b

0 (0–1)

0 (0–1)e

0 (0–1)a

0 (0–1)a g

2 (1–3)d

1 (0–2)

1 (0–2)e

2 (1–2)a f

4 (3–4)a h

0 (0–1)

0 (0–1)

1 (0–1)

1 (1–2)g h

Group 3 (ABS)
1 (1–2)
1 (1–2)
a) P < 0.001 for Group 1 versus Group 2,
b) P < 0.001 for Group 1 versus Group 3,
c) P = 0.025 for Group 2 and Group 3,
d) P = 0.001 for Group 1 and Group 2,
e) P = 0.035 for Group 1 versus Group 2,
f) P = 0.001 for Group 2 versus Group 3 ,
g) P = 0.001 for Group 1 versus Group 3,
h) P < 0.001 for Group 2 versus Group 3
ac

b

af

Ankaferd blood stopper (ABS).
*P values were calculated using the Kruskal–Wallis test.
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Figure 1. Group 1, liver microanatomy is preserved. Hepatocytes
are observed to have radial extension around the portal area,
and sinusoids appear normal. Portal inflammation, fibrosis
and prominent bile duct proliferation are not present in the
portal area. Hepatocytes appear normal and do not contain
vacuolisation.

Figure 2. Group 2, the regular radial alignment of the hepatic
cords seems to be largely lost. In addition to the prominent
dilated appearance of sinusoids and central veins, severe bile
duct proliferation and portal fibrosis and portal inflammation are
present on the right side of the photo. There is focal interphase
activity in the area marked with the arrow.

significantly lower in group 3 than in group 2 (P <
0.05) (as shown in Figure 4). Portal inflammation, focal
inflammation and confluent necrosis scores were lower
in group 3 than in group 2, but no statistically significant
difference was observed.
4. Discussion
The most important finding in our study is that ABS exerts a
hepatoprotective effect on rats that we have experimentally
developed OJ. Both histopathological and biochemical
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Figure 3. Group 2, focal interphase activity was observed in
the blue star, zone 3 confluent necrosis around the central vein
marked with arrow.

Figure 4. Group 3, hepatocytes show radial extension around
the portal area and contain mild vacuolisation. Sinusoids
appear normal. It does not contain congestion or significant
inflammation. Portal inflammation, fibrosis and prominent bile
duct proliferation are not present in the portal area.

results of this study showed better results in the OJ group
given ABS compared to the control group in terms of liver
function and tissue samples. Although ABS is known as a
haemostatic agent, it may be an alternative treatment for
liver damage due to the antioxidant and antiinflammatory
components of OJ. Obstructive jaundice is a disease that
occurs due to the blockage of the biliary intrahepatic or
extrahepatic biliary tree. The inflammatory response to
biliary obstruction results in characteristic changes in liver
morphology in early and late phases [11].
Obstructive jaundice is an area of intensive
experimental and clinical research. Bile duct ligation is the
most comprehensive model used to produce obstructive
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jaundice in animals. Bile duct ligation causes an increase
in oxidative stress markers in animals and also a decrease
in antioxidant elements. Many recent studies have focused
on the role of oxidative stress in hepatocellular damage
during cholestasis [12–14].
Free oxygen radicals (FOR) caused by oxidative
stress have an important role in the pathogenesis of
certain diseases, including cancer. FOR is produced
by parenchyma, inflammatory, and endothelial cells.
Cytotoxic effects occur as levels increase, whereas when
levels decrease, tissue damage decreases, and healing
accelerates [15].
Biliary obstruction causes changes in bilirubin
levels, bile salt metabolism and changes in enterohepatic
circulation. These changes result in significant changes in
liver functions [3].
Although the mechanism of damage due to bile salt
accumulation is not fully understood, it is most likely
due to inflammatory cell infiltration, accumulation of
hydrophobic bile acids, endotoxemia, permeability of the
mitochondrial membrane and toxic effects of FOR [16].
Reactive oxygen species are involved in necrosis
and apoptosis of hepatocytes and contribute to hepatic
stellate cell activation. Bile acids exacerbate oxidative
damage by increasing FOR release from neutrophils
and macrophages as well as increasing FOR production
in mitochondria [17]. In the chemical analysis of ABS, many
antioxidant molecules have been isolated (tocotrienols,
members of the vitamin E family, tryptophan, estriol,
galangine, apigenin, oenin, 3,4-diwanyltetrahydrofuran,
tertiary butylhydroquinone (TBHQ), thymol, butylated
hydroxyanisole (BHA), butylated hydroxytoluene (BHT),
lycopene, enoxolone/glycyrrhetinic acid or glycyrrhetic
acid and tomatine), and the concentrations of these
have not been affected by exposure to synthetic gastric
fluid. It has also been shown that ABS did not have a
genetically modified organisms (GMO) process during
the preparation process. In the same study, dioxin analyses
in the ABS sample revealed that ABS does not contain
toxic dioxin and chemical compounds like dioxin [18].
Apigenin, analysed in the content of ABS samples, is
one of the main components responsible for bleeding
and tissue degradation in the injured area. Apigenin is
known to have inhibitory effects against snake venom
metalloproteases. The predetermined antihemorrhagic
activity and apigenin content of ABS will be investigated
in future toxicology research [18,19]. In current studies,
the antioxidant, tocotrienol, has also been found in ABS.
As tocotrienol can activate apoptosis and suppress cellular
proliferation and has antiangiogenic effects, it has been
considered a potential anticancer agent [20–23]. Similarly,
ABS can activate apoptosis, regulate cellular proliferation
and suppress tumour angiogenesis. Experimental

antineoplastic activities of ABS have been demonstrated
in rats and cancer cell lines [24–29]. Since the desirable
feature of an anticancer drug is that it can kill cancer cells
and does not damage normal human cells, natural products
are widely preferred in the production of anticancer
drugs. ABS can significantly reduce the viability of cells
and is reported to have no cytotoxic properties [30]. The
antineoplastic effects of ABS were first investigated on the
presence and development of Saos-2 osteosarcoma cells.
That study showed a dose-dependent suppression of cell
proliferation and a remarkable reduction in the survival
of Saos-2 cells [31]. Göker et al. also investigated the effect
of ABS on colon cancer cells (CaCo-2) and reported a
decrease in cell viability [32]. Türk et al. showed growth
inhibitory effects on primary melanoma cells and cell lines
and that there were no cytotoxic effects on normal cells
[33].
Resistance to chemotherapeutic drugs has become one
of the current obstacles encountered in cancer treatment.
In a study by Ghasemi et al., it was shown that by changing
the genes in the oxidative phosphorylation pathway of
ABS, some melanoma cell lines can be made more sensitive
to etoposide [34]. It has also been reported that ABS may
cause leukocyte infiltrations, vascularisation and fibroblast
proliferation in the mucosal tissue, which may facilitate the
wound healing process [35]. Kaya et al. used topical ABS
on burn injury tissue and achieved a reduction in wound
diameter and inflammation, accelerated tissue fibrosis,
and wound contraction [36].
The antioxidant effects of quercetin, resveratrol and
acetylcysteine were investigated in experimental jaundice
in a study by Kawada et al. [37]. Padillo et al. performed
an experimental cholestasis study and reported that
melatonin reduced liver damage. In addition, bile duct
obstruction has been shown to be associated with the
depletion of many molecules and enzymes that possess
antioxidant properties by triggering severe oxidative stress
[16].
Ljunbuncic et al. investigated extrahepatic tissue
damage in cholestatic liver disease and reported an
association between experimental cholestasis and high
lipid peroxidation in the brain, kidney and heart [38].
ABS is a topical haemostatic agent of plant origin
that has been used in clinical practice in recent years.
This herbal medicine consists of a standard mixture
of Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera,
Alpinia officinarum and Urtica dioica [5]. In addition
to its haemostatic effects, ABS has antioxidant and
antiinflammatory effects due to the components. For
example, T. vulgaris has antioxidant effects such as the
prevention of lipid peroxidation [39]. Glycyrrhiza glabra
reduces the synthesis of lipopolysaccharide inflammatory
mediators and inhibits reactive oxygen derivatives,

1477

KOŞMAZ et al. / Turk J Med Sci
prevents liposomal membranes, lipid peroxidation, and
protects low-density lipoproteins from oxidation [40]. In
the pathogenesis of gastric mucosal injury caused by acetyl
salicylic acid (ASA) in rats, Hasgül et al. found that free
oxygen radicals were formed and there was associated
disruption of the antioxidant enzyme activity of cells and
release of lipid peroxides. ABS has been shown to reduce
oxidative and inflammatory changes caused by gastric
mucosal damage caused by ASA in rat models [41].
In an experimental rat study carried out by Akbal et
al., the gastrointestinal effect of oral high-dose ABS was
investigated. No inflammation, fibrosis, biliary destruction
or proliferation was observed in any of the groups in the
histopathological examination of the liver [42].
To the best of our knowledge, this is the first study
in literature to have examined the effect of ABS on
experimental liver obstruction jaundice. Liver tissue
samples were examined histopathologically and ABS was
seen to significantly reduce inflammation and fibrosis. In
addition, oxidative stress parameters and liver function
tests were found to be decreased compared to the control
group. Thus, the results of the study demonstrated the
hepatoprotective effect of ABS on experimental obstructive
jaundice. Nevertheless, further studies are needed to better
determine its effectiveness in clinical practice.
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